🟢 Tscan Therapeutics is trading 5.8% up today as it rebounds from a regular-session decline following TSC-101 optimism

Tscan Therapeutics is trading at $1.09, up 5.8% in after-hours trading, as the stock rebounds from a regular-session decline amid ongoing optimism for its TSC-101 program.

• The stock fell 5.5% to $1.03 during the July 13, 2026, regular session before the current uptick.
• Recent volatility follows positive ALLOHA Phase 1 data and the establishment of FDA-aligned pivotal plans for TSC-101.
• No new company-specific news or financial results have been released after the market close to explain the move.